Short Term Monitoring
every three months or less
- Is performed for lesions, that because of history of appearance, cannot be deemed benignis any condition that is harmless in the long run with absolute certainty at the initial examination.
- It enables early detection of fearless melanomas while decreasing the need of excision of clinically suspicious benign lesions.
- Any morphologic change seen at three months from baseline (short-term monitoring) requires excision.
|Significant change||Non-significant change|
|Any change other than non-significant changes||Global change in pigmentation|
|Loss or appearance of milia-like cystsThis glossary term has not yet been described.|
- Lesions remaining unchanged at 2-5-4.5 months are mostly confirmed benign on further follow-up.
Non-lentigo maligna type lesions
- Lesions observed to change during the short-term interval of 2.5-4.5 months.
Lentigo maligna Lesions
- The changes in lentigo maligna melanomaThis glossary term has not yet been described. can develop very gradually and thus a longer follow-up interval is necessary to detect some of these melanomas. A monitored interval between 6-12 months is recommended.
- An Atlas of DermoscopyThe examination of [skin lesions] with a 'dermatoscope'. This traditionally consists of a magnifier (typically x10), a non-polarised light source, a transparent plate and a liquid medium between the instrument and the skin, and allows inspection of skin lesions unobstructed by skin surface reflections. Modern dermatoscopes dispense with the use of liquid medium and instead use polarised light to cancel out skin surface reflections., Second Edition. Marghoob A. et al. CRC Press; 2012.
- Altamura, D., Avramidis, M. & Menzies, S.W., 2008, Assessment of the optimal interval for and sensitivityThis glossary term has not yet been described. of short-term sequential digital dermoscopyDermoscopy using digital images. This is used for telemedicine and monitoring. moni- toring for the diagnosisis the identification of the nature and cause of a certain phenomenon. Diagnosis is used in many different disciplines with variations in the use of logic, analytics, and experience to determine "cause and effect". In systems engineering and computer science, it is typically used to determine the causes of symptoms, mitigations, and solutions of melanomaThis glossary term has not yet been described.. Arch Dermatol, 144, 502–6.
- Altamura, D., Zalaudek, I., Sera, F., et al., 2007, Dermoscopic changes in acralPertaining to peripheral body parts, especially hands, feet, fingers, and toes. melanocyticThis glossary term has not yet been described. neviThis glossary term has not yet been described. during digital follow-up. Arch Dermatol, 143, 1372–6.
- Argenziano, G., Zalaudek, I. & Ferrara, G., 2007, Fast-growing and slow-growing melanomas. Arch Dermatol, 143, 802–3; author reply 803–4.
- Banky, J.P., Kelly, J.W., English, D.R., Yeatman, J.M. & Dowling, J.P., 2005, Incidence of new and changed nevi and melanomas detected using baseline imagesA representation of a person, animal or thing, photographed, painted or otherwise made visible. and dermoscopyThe examination of [skin lesions] with a 'dermatoscope'. This traditionally consists of a magnifier (typically x10), a non-polarised light source, a transparent plate and a liquid medium between the instrument and the skin, and allows inspection of skin lesions unobstructed by skin surface reflections. Modern dermatoscopes dispense with the use of liquid medium and instead use polarised light to cancel out skin surface reflections. in patients at high risk for melanoma. Arch Dermatol, 141, 998–1006.
- Bauer, J., Blum, A., Strohhäcker, U. & Garbe, C., 2005, Surveillance of patients at high risk for cutaneous malignantThis glossary term has not yet been described. melanoma using digital dermoscopy. Br J Dermatol, 152, 87–92.
- Dawid, M., Pehamberger, H., Wolff, K., Binder, M. & Kittler, H., 2002, Evaluation of the ability of patients to identify enlarging melanocytic nevi. Arch Dermatol, 138, 984–5. Fuller, S.R., Bowenalso known as squamous cell carcinoma in situ is a neoplastic skin disease. It can be considered as an early stage or intraepidermal form of squamous cell carcinoma. It was named after John T. Bowen, G.M., Tanner, B., Florell, S.R. & Grossman, D., 2007, Digital dermoscopic monitoring of atypical neviNevi that clinically look like melanoma but that histopathologically are not melanomas in patients at risk for melanoma. Dermatol Surg, 33, 1198–206; discussion 1205–6.
- Haenssle, H.A., Krueger, U., Vente, C., et al., 2006, Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. J Invest Dermatol, 126, 980–5.
- Kittler, H. & Binder, M., 2001, Risks and benefits of sequential imaging of melanocytic skin lesions in patients with multiple atypical nevi. Arch Dermatol, 137, 1590–5.
- Kittler, H. & Binder, M., 2002, Follow-up of melanocytic skin lesions with digital dermoscopy: risks and benefits. Archives of Dermatology, 138, 1379.
- Kittler, H., Pehamberger, H., Wolff, K. & Binder, M., 2000a, Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patternsThis glossary term has not yet been described. of modifications observed in early melanoma, atypical nevi, and common nevi. J Am Acad Dermatol, 43, 467–76.
- Kittler, H., Seltenheim, M., Dawid, M., et al., 2000b, Frequency and characteristics of enlarging common melanocytic nevi. Arch Dermatol, 136, 316–20.
- Menzies, S.W., Gutenev, A., Avramidis, M., Batrac, A. & McCarthy, W.H., 2001, Short-term digital surface microscopic monitoring of atypical or changing mela- nocytic lesions. Arch Dermatol, 137, 1583–9.
- Robinson, J. & Nickoloff, B., 2004, Digital epiluminescence microscopy monitoring of high-risk patients. Arch Dermatol, 140, 49–56.
- Zalaudek, I., Karin, S., Marghoob, A., et al., 2011, Frequency of dermoscopic nevus subtypes by ageprocess of becoming older and body sitedescribes the area of the body: a Cross-sectional Study. Arch Dermatol, 147, 663–70.